What Pratia does

Pratia, headquartered in Warsaw and operationally based in Katowice, is one of the largest clinical research site networks in Europe and positions itself as the world's leading oncology research network. The company operates 100+ sites across 8 countries (Poland, Czechia, Slovakia, Bulgaria, Germany, Spain, the United States, and Turkey), reaching 65 million+ patients through integrated oncology research sites and covering 85% of all therapeutic areas. Pratia runs up to 600+ active clinical trials annually, with oncology representing more than 30% of the portfolio across 7 owned exclusive oncology units. Its core technology is Hyggio, a proprietary platform that powers the global site network with unified eSource (FDA/EMA-compliant), CTMS, finance and budget modules, remote monitoring for source data verification, and a patient recruitment module that operates across an enterprise-wide data warehouse.

Pratia serves pharmaceutical and biotech sponsors and CROs through direct enterprise sales, RFP processes, and partnership relationships, offering two principal service lines: End-to-End Site Operations (full study execution from feasibility and start-up through recruitment, conduct, data collection, and close-out, delivered across dedicated and embedded site models) and Site Service Provision (SSP), which deploys qualified study coordinators and clinical research professionals to multicenter studies under the client sponsor's oversight. Revenue is generated via professional and managed service fees tied to trial execution, with additional biosample collection services aligned to IVDR for IVD manufacturers. Pratia does not publicly disclose pricing; engagements are structured via RFP.

The company is a subsidiary of Humaneva Group (which also owns Kapadi and Hyggio and employs approximately 2,000 people across four continents and twelve countries). Pratia's growth strategy has been defined by aggressive geographic and therapeutic expansion through acquisitions and partnerships: CRC (Czechia/Slovakia, January 2025), a partnership with Essen Healthcare in the Bronx, New York (April 2025), the P1 Trials early-phase oncology network in the United States (December 2025), and Atlas in Turkey (April 2026), alongside organic site openings such as the new neurology-focused Wrocław site (October 2025) and a near-doubling of the Katowice Oncology site. Leadership transitioned in January 2026 with Łukasz Bęczkowski appointed Global CEO, Tomek Dąbrowski moving to Executive Chair (while continuing as Humaneva Group CEO), and Tomasz Groń promoted to VP Operations Europe.

Name

Pratia

Legal name

PRATIA S.A.

Website

https://pratia.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Pratia operates one of Europe's largest clinical research site networks, with 100+ sites in 8 countries serving pharma sponsors and CROs through end-to-end site operations, staffing services, and the proprietary Hyggio clinical trial technology platform.

Ownership category

akta.pro rank

Product category

Clinical Research Site Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA)

Keywords

• Clinical trial site network
• Oncology research services
• Clinical research operations
• Site service provision
• Patient recruitment services

Headquarters

HQ city

Katowice

HQ country

Poland

HQ region

Europe

Offices15 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. End-to-End Site Operations: Pratia provides full operational leadership at the site level, managing clinical trial execution from start-up through close-out across its own dedicated research sites and embedded units. This includes feasibility and study start-up, patient recruitment and retention, trial conduct and data collection, and study close-out. Revenue is generated through service fees tied to trial execution across therapeutic areas including oncology, vaccines, specialty care, and early-phase research.
2. Site Service Provision (SSP): Pratia deploys highly qualified Study Coordinators and specialized clinical research professionals to support multicenter studies. With more than 20 years of experience, SSP provides staffing solutions including Data Entry Specialists, Study Coordinators, Nurses, site identification, feasibility assessments, quality control, and CTA management. Revenue is generated through staffing and service fees.
3. Biosample Collection Services: Pratia provides comprehensive biosample collection services for clinical trials and IVDR studies, including prospective biological sample collection, sample processing, storage in ULT freezers at -80°C, and shipment coordination. Services are also provided for IVD manufacturers under EU Regulation 2017/746 (IVDR).

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Core offering

Pratia operates one of the largest clinical research site networks in Europe, with 100+ sites across 8 countries, providing end-to-end clinical trial execution services for pharmaceutical and biotechnology sponsors and CROs. Services span feasibility, study start-up, patient recruitment and retention, trial conduct, data collection, biosampling, and study close-out across dedicated sites, embedded hospital units, and hybrid models. Its proprietary Hyggio technology platform unifies eSource, CTMS, remote monitoring, and patient recruitment across the entire network.

Product overview

Pratia operates as a clinical research site network offering a portfolio of integrated services and proprietary technology. The core platform consists of Hyggio, Pratia's proprietary technology system powering eSource, CTMS, remote monitoring, and patient recruitment capabilities. Service offerings include End-to-End Site Operations (full study delivery from start-up to close-out) and Site Service Provision (SSP - staffing and operational support). Pratia provides specialized therapeutic services in oncology (30%+ of portfolio, with 7 exclusive oncology units), vaccine research, Phase I studies, specialty care across 12+ medical specialties, and biosampling services. The global network spans 100+ sites across 8 countries. Recent acquisitions include P1 Trials (US oncology), CRC (Czechia/Slovakia), and Atlas (Turkey), expanding geographic reach. Patient engagement is supported through the proprietary platform, dedicated outreach campaigns, and the Patients of Tomorrow international awareness initiative.

Differentiator

Problem solved

Functional benefit

Brands

• Hyggio: Proprietary technology platform powering Pratia's site network; features include eSource, CTMS, remote monitoring, patient recruitment, unified data management, and analytics.

Products and services

• Hyggio Technology Platform Proprietary clinical trial technology platform powering Pratia's global site network. Features include eSource for FDA/EMA-compliant electronic medical documentation, CTMS for unified clinical trial management, remote monitoring for SDV/SDR protocol verification, and a patient recruitment module with a dedicated patient data warehouse. Delivers operational efficiencies and cost savings for sponsors and CROs running multi-site trials.
• End-to-End Site Operations Full operational leadership at the site level covering clinical trial delivery from start-up through close-out. Includes feasibility and study start-up, patient recruitment and retention, trial conduct and data collection, and study close-out and compliance, delivered across dedicated and embedded site models. Sold to pharma and biotech sponsors.
• Site Service Provision (SSP) Staffing and operational support model with 20+ years of experience, deploying highly qualified Study Coordinators, Data Entry Specialists, Nurses, and other specialized clinical research professionals to support multicenter studies at external sites. Provides site identification, feasibility assessments, quality control, and CTA management while clients retain operational oversight. Sold to CROs and sponsors.
• Patient Engagement Function Specialized patient engagement service combining strategic expertise, integrated digital tools, and operational support to accelerate patient enrollment, streamline workflows, and improve retention. Includes multichannel patient outreach (digital, print, radio, outdoor), owned patient databases, and international awareness campaigns such as Patients of Tomorrow across 8 countries. Delivered to sponsors running trials in Pratia's network.
• Biosampling Services Comprehensive biological sample services for clinical trials and IVDR studies, including prospective biosample collection, processing, 24/7 temperature-monitored storage in ULT freezers at -80°C, and shipment coordination. Supports biobanks, biomarker analysis, pharmacokinetics, personalized medicine, and IVD manufacturers under EU Regulation 2017/746 (IVDR).
• Oncology Research Services Therapeutic area specialization representing over 30% of Pratia's clinical trial portfolio, with 7 owned exclusive oncology units and 15.2 million oncology patients in reach across the network. Covers complex protocols, biomarker-driven designs, and rapid patient recruitment for cutting-edge cancer treatments, including early-phase oncology in the US through P1 Trials.
• Vaccine Research Services Phase I-IV vaccine research for adult and pediatric populations, with expertise in mRNA, viral vector, and recombinant protein technologies. Studies cover COVID-19, Influenza, HIV, HPV, and other indications. Consistently achieves 100-300% of recruitment targets. Recognized with the 2025 Vaccine Industry Excellence Award for Best Clinical Research Network.
• Phase I Clinical Research Services Phase I flagship site in Warsaw, Poland with over 20 years of experience, having completed 280+ clinical research projects and 65 audits including 2 FDA inspections with NAI results. Specializes in First-in-Human studies, SAD/MAD, bioequivalence, PK/PD, and tobacco risk evaluation. MTZ Clinical Research powered by Pratia extends early-phase capabilities with bioequivalence and Phase III studies.
• Specialty Care Research Services Specialty care research covering vascular diseases, cardiology, nephrology, dermatology, rheumatology, gastrology, urology, pulmonology, hematology, metabolic diseases, pediatrics, and surgery across Pratia's 100+ site network spanning 85% of all therapeutic areas.
• Global Site Network Access Access to Pratia's integrated global network of 100+ dedicated and embedded research sites across 8 countries (Poland, Czechia, Slovakia, Bulgaria, Germany, Spain, USA, Turkey), with centralized contracting (one contract, one budget per country), 65 million+ patient reach, and uniform operational delivery through the Hyggio platform. Sold to sponsors and CROs running multi-country trials.

Quantifiable outcome

• 90% Net Promoter Score across clinical sites
• +5 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

16 partnerships are on record, tiered core and secondary.

• AtlascoreStrategic or Co-development Partner · 15 April 2026Pratia announced a majority investment into Atlas, one of Turkey's leading providers of services supporting clinical trials across the country. Founded in 2002 in Istanbul, Atlas provides Site Service Provision across Turkey through more than 240 field staff, covering over 19 therapeutic areas including oncology, cardiology, and neurology. This investment marks Pratia's entry into the Turkish market, which represents a rapidly growing clinical research market estimated at USD 520 million in 2024.
• P1 TrialscoreStrategic or Co-development Partner · 8 December 2025Pratia LLC acquired a majority stake in P1 Trials, a U.S.-based early phase oncology clinical research network. P1 Trials operates community-based oncology practices in WA, TX, and IN. The partnership establishes one of the few global research ecosystems dedicated exclusively to early-phase oncology, connecting North America and Europe. Pratia's reach of 65 million+ patients in Europe is extended through P1's US network in the world's largest oncology research market.
• Premium ClinicsecondaryStrategic or Co-development Partner · 1 October 2025Pratia's new Wrocław research site was developed in collaboration with Premium Clinic, combining Pratia's clinical research expertise with Premium Clinic's medical experience and established patient trust. The site focuses on neurology studies including epilepsy, migraine, Alzheimer's disease, and sleep disorders.
• BiomapassecondaryStrategic or Co-development Partner · 13 May 2025Biomapas participated in Pratia's webinar 'Smarter partnerships, better outcomes' exploring how CROs, site networks, and SMOs are reshaping clinical trial collaboration. The webinar featured expert panels from Pratia, Biomapas, and Medrial.
• MedrialsecondaryStrategic or Co-development Partner · 13 May 2025Medrial participated in Pratia's webinar 'Smarter partnerships, better outcomes' exploring how CROs, site networks, and SMOs are reshaping clinical trial collaboration. The webinar featured expert panels from Pratia, Biomapas, and Medrial.
• AMRC (Association of Multisite Research Corporations)coreStrategic or Co-development Partner · 1 April 2025Pratia became the 15th member of AMRC, a nonprofit organization dedicated to advancing multisite clinical research corporations in the global clinical trial ecosystem. AMRC provides a platform to advocate for MCRCs globally, advance a new model for trial delivery, and collaborate with fellow AMRC members to shape the future of clinical research.
• CRC (Clinical Research Centre)coreStrategic or Co-development Partner · 9 January 2025Pratia expanded into Slovakia and further diversified its business in Czech Republic through the acquisition of CRC. CRC provides access to a network of over 160 investigators across both countries, conducting clinical trials across a wide range of therapeutic areas including oncology. CRC also offers comprehensive site services and home care solutions, with a synergy between site network and home care services advantageous for hybrid clinical trials with DCT elements.
• Essen HealthcarecoreStrategic or Co-development Partner · 1 January 2025Pratia partnered with Essen Healthcare, a trusted healthcare network serving the Bronx, New York. This collaboration aims to bring innovative clinical trial opportunities to the borough's underserved populations. Essen Healthcare serves nearly 1.4 million people and operates 45 clinical spaces. Studies will cover metabolic disorders, cardiology, pulmonology, and mental health. The partnership addresses FDA's mission to increase diversity in clinical research.
• Hermes Salud FoundationsecondaryStrategic or Co-development Partner · 1 January 2024Pratia established a partnership with the Spanish Hermes Salud Foundation, which operates hospitals in Elche, Madrid, and Vigo, expanding Pratia's site network presence in Spain.
• HLA Universitario Moncloa HospitalsecondaryStrategic or Co-development Partner · 1 January 2024Pratia established a partnership with HLA Universitario Moncloa Hospital in Madrid, Spain, strengthening Pratia's hospital-based research site network in Spain.
• Jagiellonian University Collegium MedicumsecondaryStrategic or Co-development Partner · 1 January 2024Pratia Kraków supports the next generation of clinical trials specialists through partnerships with Jagiellonian University's Collegium Medicum. Students from postgraduate programs gain hands-on experience at the research site, learning from Investigators, Study Teams, and operational experts.
• Andrzej Frycz Modrzewski UniversitysecondaryStrategic or Co-development Partner · 1 January 2024Pratia Kraków supports the next generation of clinical trials specialists through partnerships with Andrzej Frycz Modrzewski University. Students from postgraduate programs gain hands-on experience at the research site.
• HM Montepríncipe (UICHI)secondaryStrategic or Co-development Partner · 1 January 2022Pratia established sites with UICHI, the oncology unit of Clínical HM Montepríncipe and Llobergat in Spain, expanding its oncology research capabilities in the Spanish market.
• HyggiocoreTechnology or Integration · 1 January 2020Hyggio is Pratia's proprietary technology platform that powers the global site network. The software's features including eSource, CTMS, remote monitoring, patient recruitment, and more drive operational efficiencies across all sites while delivering cost savings for clients. Hyggio is part of Humaneva Group alongside Pratia and Kapadi.
• Humaneva GroupcoreOthersPratia is part of Humaneva Group, a parent company that unites the clinical research landscape for the betterment of patients worldwide. Humaneva Group includes Pratia (site network), Kapadi, and Hyggio. Tomek Dąbrowski, co-founder and former CEO of Pratia, serves as Humaneva Group CEO. Humaneva Group employs approximately 2,000 people across four continents and twelve countries.
• SCRS (Society for Clinical Research Sites)secondaryOthersPratia is a member of SCRS, a global organization dedicated to representing the voice of clinical research sites and advancing site-level interests in the clinical trial ecosystem.

Scale indicators22 records

Recent moves9 records

Expansion highlights7 records

Broad incumbents

• Fortrea (formerly Labcorp Drug Development): Global CRO carved out of Labcorp in 2023 with embedded site solutions and FSP offerings. Direct competitor to Pratia in multi-country site operations and a potential Site Service Provision customer.
• Medpace: Mid-to-large global CRO with strong site relationships and growing site network footprint. Competes with Pratia for oncology and specialty trial sponsorships, particularly in Europe and North America.
• Syneos Health: Global biopharma solutions organization (private under Elliott Investment Management since 2023) combining CRO services with site network capabilities. Comparable to Pratia in offering sponsors integrated clinical delivery models.
• ICON plc: Top-3 global CRO with substantial site network capabilities following PRA Health Sciences acquisition. Competes with Pratia for oncology and multi-country trial awards and is a major sponsor-customer of SMOs.
• IQVIA: Largest global CRO with embedded site solutions (IQVIA Site Network) and broad therapeutic coverage. Competes with Pratia for multi-country trial execution while also serving as a customer through Pratia's Site Service Provision model.
• WCG (WIRB-Copernicus Group): Clinical research solutions provider offering IRB, technology, and site enablement services to sponsors and sites. Adjacent competitor focused on the site enablement layer where Pratia's Hyggio platform also competes.

Direct peers

• Celerion: Specialized clinical research organization focused on early-phase and bioequivalence studies with clinics in North America and Europe. Closely comparable to Pratia's Warsaw Phase I flagship site capabilities.
• Velocity Clinical Research: US-headquartered integrated clinical research site network acquired by Kohlberg & Company in 2021, operating 25+ sites across the US. Direct comparable to Pratia's site network model with multi-therapeutic coverage and dedicated Phase I capabilities.

Emerging players

• Sanguine Biosciences: Decentralized clinical trial site network focused on patient recruitment and biospecimen collection. Comparable to Pratia's patient engagement function and biosample services, with overlapping sponsor customer base.

Regional players

• CMAX Clinical Research: Australia-based early-phase clinical research unit comparable to Pratia's Phase I flagship site in scope and offering. Regional peer that competes for global sponsor Phase I programs outside the European and US markets Pratia serves.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pratia

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pratia